Tyra Biosciences to Participate in Upcoming Investor Conferences
Tyra Biosciences (Nasdaq: TYRA) announced plans to participate in the Guggenheim and Jefferies healthcare investor conferences in November 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tyra Biosciences (Nasdaq: TYRA) announced plans to participate in the Guggenheim and Jefferies healthcare investor conferences in November 2026.
The company will hold one-on-one meetings in Boston on November 10 at Guggenheim’s conference. Its Jefferies conference participation in London includes a hybrid presentation on November 16 at 11:30 AM GMT and one-on-one investor meetings. A live webcast and subsequent replay will be available through its investor website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Guggenheim 3rd Annual Healthcare Innovation Conference 2026
Format: One-on-one investor meetings
Date/Time: November 10, 2026
Location: Boston, MA
Jefferies Global Healthcare Conference in
Format: Hybrid presentation and one-on-one investor meetings
Presentation Date/Time: Monday, November 16, 2026 at 11:30 AM GMT
A live webcast of the Jefferies presentation can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help TYRA design and predict which candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA's lead precision medicine stemming from SNÅP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for low grade upper tract urothelial cancer, low grade intermediate risk non-muscle invasive bladder cancer and achondroplasia. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-participate-in-upcoming-investor-conferences-302930923.html
SOURCE Tyra Biosciences